Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer

[1]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[2]  Bin Zhou,et al.  Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers , 2016, Journal of experimental & clinical cancer research : CR.

[3]  M. Pascual-Geler,et al.  Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk. , 2016, Urologic oncology.

[4]  D. Heymann,et al.  miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors , 2016, Oncotarget.

[5]  M. Hsiao,et al.  MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma , 2016, Oncotarget.

[6]  Hongcheng Liu,et al.  microRNA-188 is downregulated in oral squamous cell carcinoma and inhibits proliferation and invasion by targeting SIX1 , 2016, Tumor Biology.

[7]  Yang Yu,et al.  The role of mesenchymal stem cells in promoting the transformation of androgen-dependent human prostate cancer cells into androgen-independent manner , 2016, Scientific Reports.

[8]  Lei Yu,et al.  MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. , 2015, Journal of hepatology.

[9]  Wei-De Zhong,et al.  miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer , 2015, Clinical Cancer Research.

[10]  Yuzhuo Wang,et al.  miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression , 2015, Oncotarget.

[11]  Yanqiong Zhang,et al.  Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway , 2014, Molecular Cancer.

[12]  P. Zhang,et al.  Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer. , 2014, World journal of gastroenterology.

[13]  Liang Zhou,et al.  CC Chemokine Ligand 18 Correlates with Malignant Progression of Prostate Cancer , 2014, BioMed research international.

[14]  Chin-Lee Wu,et al.  MicroRNA‐224 inhibits progression of human prostate cancer by downregulating TRIB1 , 2014, International journal of cancer.

[15]  Tao Yu,et al.  MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway , 2014, Oncogene.

[16]  N. Weigel,et al.  Androgen receptors in hormone-dependent and castration-resistant prostate cancer. , 2013, Pharmacology & therapeutics.

[17]  Xin Fu,et al.  Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients , 2013, BMC Genomics.

[18]  Takashi Suzuki,et al.  Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer , 2013, The Prostate.

[19]  Jan-Gowth Chang,et al.  Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma , 2013, Medical Oncology.

[20]  Stacey A. Kenfield,et al.  A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer , 2012, Clinical Cancer Research.

[21]  P. Blackshear,et al.  Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements , 2012, Nucleic acids research.

[22]  Ananth Grama,et al.  Modularity detection in protein-protein interaction networks , 2011, BMC Research Notes.

[23]  J. Stanford,et al.  Genetic variation in RNASEL and risk for prostate cancer in a population‐based case–control study , 2011, The Prostate.

[24]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[25]  B. Coulombe.  Faculty Opinions recommendation of The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. , 2007 .

[26]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[27]  M. Guan,et al.  Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: correlation with Gleason score , 2005, Journal of Clinical Pathology.

[28]  R. Silverman,et al.  Mapping of the human RNASEL promoter and expression in cancer and normal cells. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  F. McKeon.  p63 and p73 in tumor suppression and promotion. , 2004, Cancer research and treatment : official journal of Korean Cancer Association.

[30]  A. Yang,et al.  On the shoulders of giants: p63, p73 and the rise of p53. , 2002, Trends in genetics : TIG.

[31]  A. Yang,et al.  p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.

[32]  R. Moyzis,et al.  Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system. , 1996, Genomics.

[33]  C. Sherr.  Mammalian G1 cyclins and cell cycle progression. , 1995, Proceedings of the Association of American Physicians.

[34]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .